Welcome to our dedicated page for Morphic Holding news (Ticker: MORF), a resource for investors and traders seeking the latest updates and insights on Morphic Holding stock.
Morphic Holding (MORF) delivers innovative oral integrin therapies targeting chronic diseases through advanced small molecule research. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access verified information about MORF-057 clinical trials, partnership announcements, and financial disclosures. Our curated collection ensures you stay informed about Morphic's progress in transforming autoimmune and inflammatory disease treatments through its proprietary MInT technology platform.
Discover press releases covering key areas: clinical trial results, research collaborations, regulatory filings, and financial performance. Bookmark this page for real-time updates on Morphic's pipeline advancements and scientific breakthroughs in oral integrin therapeutics.
Eli Lilly and Company (NYSE: LLY) has successfully completed its acquisition of Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company developing oral integrin therapies for treating serious chronic diseases. The acquisition, valued at $57 per share, broadens Lilly's immunology pipeline, particularly in the field of inflammatory bowel disease (IBD).
Key highlights include:
- Acquisition of Morphic's oral integrin therapies, including MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for IBD
- Reinforcement of Lilly's strategy to deliver first or best-in-class therapies in gastroenterology
- Potential for researching combination treatments to better serve patients
- Delisting of Morphic's common stock from The Nasdaq Global Market
Eli Lilly and Company (NYSE: LLY) has entered a definitive agreement to acquire Morphic Holding (NASDAQ: MORF) for $57 per share in cash, totaling approximately $3.2 billion. This acquisition aims to bolster Lilly's immunology pipeline with Morphic's lead molecule, MORF-057, an oral integrin therapy currently in Phase 2 studies for treating ulcerative colitis and Crohn's disease. The transaction has been approved by both companies' boards and is expected to close in Q3 2024, subject to standard conditions. The offer represents a 79% premium to Morphic's stock price as of July 5, 2024. Morphic's board recommends shareholders tender their shares.
Morphic Therapeutic (Nasdaq: MORF) announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with members of the company's management team. The session is scheduled for June 5th at 10:30 AM ET and will be webcast live on Morphic's website, with an archived replay available afterward. Morphic is a biotechnology firm focused on developing oral integrin therapies for chronic diseases.
Morphic Therapeutic (Nasdaq: MORF) presented groundbreaking preclinical data at the Digestive Disease Week 2024, showcasing the real-time visualization of their small molecule α4β7 inhibitor, MT-108, on B cell movement in the gut. Using Spinning Disk Intravital Microscopy (IVM), the study demonstrated that MT-108 significantly increases the velocity and flux of lymphocytes in gut-associated lymphoid tissues (GALT), comparable to the anti-α4β7 antibody DATK32. This inhibition prevents lymphocyte migration into gut tissues, a key factor in inflammatory bowel disease. The data highlights MT-108's potent and selective impact on immune cell trafficking similar to monoclonal antibodies, providing a new avenue for oral integrin therapies.
Morphic Therapeutic (Nasdaq: MORF) will participate in the 2024 RBC Capital Markets Global Healthcare Conference where Dr. Marc Schegerin, COO and CFO, will engage in a fireside chat on May 15th. The company is focused on developing oral integrin therapies for chronic diseases.
FAQ
What is the current stock price of Morphic Holding (MORF)?
What is the market cap of Morphic Holding (MORF)?
